OXFORD, England, September 12, 2012 /PRNewswire/ --
OBN's Annual Awards Dinner, last night celebrated the achievements and major success stories in biotech, medtech and diagnostics over the past year at a black tie event at The Ashmolean Museum, Oxford. The Awards sought to highlight the many achievements of the UK's bioscience sector in raising funds, executing deals and supporting innovation, as well as the addition of two new awards for 2012 to recognise the "Highest Impact Investor" and the "Best Pharma BD&L Team".
The 2012 award winners were:
Vertex, Best New Biotech Product
Award Presented by Berkley Group
For the second year running, Vertex has had a first in class chemical entity approved by the FDA and the EMEA. Kalydeco[TM] is an ion channel inhibitor designed to address one of the causes of cystic fibrosis and is the first treatment that addresses the underlying etiology of the disease.
Oxtex, Best New Medtech Product
Award Presented by JA Kemp
Oxtex is a manufacturer of anisotropic self-inflating tissue expanders for use in reconstructive plastic surgery and restorative dentistry. For the first time, surgeons will be able to accurately and predictably control the direction, the timing, and rate of the material's expansion in the body significantly reducing the risk of soft tissue damage and associated complications.
London Pharma, Best Emerging Biotech
Award Presented by James Cowper
London Pharma, founded in 2006, is a drug delivery company developing, in the main, already known and registered compounds delivered sublingually through its own unique system. London Pharma's sublingual delivery route is shown to be faste
Copyright©2012 PR Newswire.
All rights reserved